JAK1/TYK2-IN-3

• UNSPSC Description:

  JAK1/TYK2-IN-3 is a potent, selective and orally active dual TYK2/JAK1 inhibitor with IC50 values of 6 and 37 nM, respectively. JAK1/TYK2-IN-3 also shows selectively relative to JAK2 (IC50=140 nM) and JAK3 (IC50=362 nM). JAK1/TYK2-IN-3 shows anti-inflammatory effect by regulating the expression of related TYK2/JAK1-regulated genes, as well as the formation of Th1, Th2, and Th17 cells[1].

• Target Antigen:

  JAK

• Type:

  Reference compound

• Related Pathways:

  Epigenetics;JAK/STAT Signaling;Protein Tyrosine Kinase/RTK;Stem Cell/Wnt

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/jak1-tyk2-in-3.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C1NCCC12CCN(C3=NC(NC4=CN(C(F)F)N=C4)=NC=C3C)CC2

• Molecular Weight:

  377.39

• References & Citations:

  [1]Yang T, et al. Identification of a Novel 2,8-Diazaspiro[4.5]decan-1-one Derivative as a Potent and Selective Dual TYK2/JAK1 Inhibitor for the Treatment of Inflammatory Bowel Disease. J Med Chem. 2022; 65(4):3151-3172.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  2734918-37-5